National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns

Association Clinique Thérapeutique Infantile du val de Marne2,500 enrolled

Overview

After 7 then 13 valent pneumococcal conjugate vaccine (PCV) implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status.

For children under 18, hospitalized for IPD, the following data will be analyzed: risk factors, vaccination status, severity signs , treatment during hospitalization, biological analysis, the clinical location of the disease.

Study Type

OBSERVATIONAL

Enrollment

2,500

Conditions

Pneumococcal Infections Pneumococcal Conjugate Vaccine Antibiotic Treatment Mortality

Eligibility

Sex: ALLMin age: 1 DayMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood polymerase chain reaction (PCR). Exclusion Criteria: * Pneumococcal strain not transmetted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory

Outcomes

Primary Outcomes

Severity of invasive pneumococcal disease

Number of severe cases according to age and pneumococcal serotypes distribution

Time frame: before hospital discharge

Secondary Outcomes

Impact of vaccines

Number of invasive pneumococcal disease according to vaccine serotypes